MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a health professional report with the FDA on 2019-05-07 for THERASPHERE 4.5 GBQ N/A manufactured by Biocompatibles Uk Ltd.
[144280014]
Btg medical assessment: patient is a (b)(6) male with numerous comorbid problems with a new diagnosis of (b)(6) and hepatocellular carcinoma. He was found to have associated portal vein thrombosis, and very advanced hepatocellular carcinoma. Extension of pv thrombosis, activity of (b)(6) not documented, very advanced stage hcc is a contra indication for specific treatment of cancer and a indication of best supportive care). Alt/ast/bilirubin/albumin/% tumor involvement/child pugh/ascites assessment are not documented. Following a discussion of treatment options he elected to proceed with therasphere treatment. He underwent the preliminary mapping study and was found to have significant narrowing of his celiac artery requiring angioplasty. His vascular anatomy was otherwise favorable to proceed. It is not documented if the maa target the tumor and the pvt, as it has been deeply demonstrated that the absence of maa targeting is of bad prognosis for response and a good marker for liver failure after therasphere treatment. The therasphere treatment was delivered as planned on (b)(6) 2019 with no immediate complications or problems. He was discharged on (b)(6) 2019. At home he continued to feel well. He is on coumadin for factor 5 leiden deficiency and had a routine inr performed on (b)(6) 2019 which returned at 12. He was admitted to south seminole hospital and on admission was found to be jaundiced with markedly elevated liver function tests. A ct scan revealed increase in biliary obstruction but not amenable to percutaneous drainage. He underwent aggressive supportive care prior to transfer to hospice. On admission here he had worsening hepatic encephalopathy and worsening liver and kidney failure. The patient was transferred to inpatient hospice on (b)(6) 2019 and died on the hospice unit on (b)(6) 2019. Conclusion: patient with end stage hcc treated with therasphere as a rescue treatment after patient agreement. Therasphere led to worsening of pre-existing patient condition and led to premature death, according to the documentation provided patient life expectancy was <12 weeks before treatment. Serious adverse events: anticipated in the ifu/risk management documentation. Reporter's assessment of relatedness: the reporting physician determines this to be unexpected, serious and related to therasphere. As per the documentation received from the reporter "the patient had few treatment options and a very short life expectancy without treatment. The treatment was delivered without problem but he had worsening liver function 2 weeks after receiving the therasphere treatment that ultimately led to his death. " a review of manufacturing records was performed for lot number 1999121 and summarised as follows: there were no deviations for this batch. There were no anomalies noted during the batch review. The dose, release testing and batch met all acceptance criteria. The batch was manufactured and approved for release as per all applicable procedures. No other information is available that could confirm/deny the alleged event. All reported events are anticipated as per the ifu/risk management documentation. At this time this report is considered final.
Patient Sequence No: 1, Text Type: N, H10
[144280015]
Patient is a (b)(6) male with numerous comorbid problems with a new diagnosis of (b)(6) and hepatocellular carcinoma. He was found to have associated portal vein thrombosis, and very advanced hepatocellular carcinoma. Following a discussion of treatment options he elected to proceed with therasphere treatment. He underwent the preliminary mapping study and was found to have significant narrowing of his celiac artery requiring angioplasty. His vascular anatomy was otherwise favorable to proceed. Post mapping he had worsening of his upper abdominal pain and hiccups. The treating physician met with him again on (b)(6) and on the day of the procedure (b)(6) and each time reviewed the pros and cons of proceeding. The patient very much wanted to move forward with the treatment. The therasphere treatment was delivered as planned on (b)(6) 2019 with no immediate complications or problems. He was admitted for observation and actually felt better than he had for sometime. He was discharged on (b)(6) 2019. At home he continued to feel well. He is on coumadin for factor 5 leiden deficiency and had a routine inr performed on (b)(6) 2019 which returned at 12. He was admitted to (b)(6) hospital and on admission was found to be jaundiced with markedly elevated liver function tests. The patient and his wife desired transfer to (b)(6) and in the evening of (b)(6) 2019 was transferred. A ct scan revealed increase in biliary obstruction but not amenable to percutaneous drainage. He underwent aggressive supportive care prior to transfer to hospice. He was dnr during the hospitalization. On admission he had worsening hepatic encephalopathy and worsening liver and kidney failure. The patient was transferred to inpatient hospice on (b)(6) 2019 and died on the hospice unit on (b)(6) 2019.
Patient Sequence No: 1, Text Type: D, B5
| Report Number | 3002124543-2019-00037 |
| MDR Report Key | 8586403 |
| Report Source | HEALTH PROFESSIONAL |
| Date Received | 2019-05-07 |
| Date of Report | 2019-04-16 |
| Date of Event | 2019-04-03 |
| Date Mfgr Received | 2019-04-16 |
| Date Added to Maude | 2019-05-07 |
| Event Key | 0 |
| Report Source Code | Manufacturer report |
| Manufacturer Link | Y |
| Number of Patients in Event | 0 |
| Adverse Event Flag | 3 |
| Product Problem Flag | 0 |
| Reprocessed and Reused Flag | 3 |
| Reporter Occupation | OTHER HEALTH CARE PROFESSIONAL |
| Health Professional | 3 |
| Initial Report to FDA | 3 |
| Report to FDA | 3 |
| Event Location | 3 |
| Manufacturer Contact | MS SANDRA BAUSBACK-ABALLO |
| Manufacturer Street | 300 FOUR FALLS CORPORATE CENTE 300 CONSHOHOCKEN STATE ROAD |
| Manufacturer City | WEST CONSHOHOCKEN, PA 194282998 |
| Manufacturer Country | US |
| Manufacturer Postal | 194282998 |
| Manufacturer Phone | 6103311537 |
| Manufacturer G1 | BIOCOMPATIBLES UK |
| Manufacturer Street | CHAPMAN HOUSE WEYDON LANE |
| Manufacturer City | FARNHAM, SURREY GU9 8QL |
| Manufacturer Country | UK |
| Manufacturer Postal Code | GU9 8QL |
| Single Use | 3 |
| Previous Use Code | 3 |
| Event Type | 3 |
| Type of Report | 3 |
| Brand Name | THERASPHERE |
| Generic Name | YTTRIUM-90 GLASS MICROSPHERES, PRODUCT CODE: NAW |
| Product Code | NAW |
| Date Received | 2019-05-07 |
| Model Number | 4.5 GBQ |
| Catalog Number | N/A |
| Lot Number | 1999121 |
| Operator | HEALTH PROFESSIONAL |
| Device Availability | N |
| Device Eval'ed by Mfgr | R |
| Device Sequence No | 1 |
| Device Event Key | 0 |
| Manufacturer | BIOCOMPATIBLES UK LTD |
| Manufacturer Address | CHAPMAN HOUSE FARNHAM BUS PARK WEYDON LANE FARNHAM, SURREY GU9 8QL UK GU9 8QL |
| Patient Number | Treatment | Outcome | Date |
|---|---|---|---|
| 1 | 0 | 1. Death; 2. Hospitalization | 2019-05-07 |